Medistim ASA (0OCD)
London Exchange · UK · prices in NOK · close of 23 Oct 2026
Key indicators
| Last close | NOK 300.00 |
|---|---|
| 52-week range | 187.00 – 302.50 |
| Return, 1 month / 3 months | +22.0% / +32.2% |
| Return, 1 year / 3 years | +33.5% / +78.8% |
| Trend | Uptrend |
| RSI (14) | 79 |
| Volatility (1 year) | 42.8% |
| Worst drawdown (1 year) | -34.0% |
| Average daily value traded | 0.22M NOK |
| Dividend yield | 2.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Medistim ASA is a medical technology company based in Oslo, Norway. It develops and supplies equipment used by cardiac and vascular surgeons to check blood flow and vessel quality during operations. Its products include flow measurement and ultrasound imaging systems used in coronary artery bypass and other vascular procedures. The company serves hospitals and surgical teams, and it also provides related probes and accessories used with its monitoring equipment.
On this site Medistim ASA appears as a stock on the London Exchange (UK), code 0OCD, with prices in Norwegian kroner (NOK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Medistim ASA (0OCD) trades on the London Exchange in UK. It last closed at NOK 300.00 on 23 October 2026.
Its price-based Market X-Ray is 62 out of 100 (a fair price profile), ranking 1,182 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 33.5% and over the last three months it rose 32.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 88 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 28.9% | ||
| From 52-week high | 0.0% | ||
| Momentum | 81 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 32.2% | ||
| 6-month return | 37.0% | ||
| 12-month return, skipping the last month | 9.4% | ||
| Stability (higher is calmer) | 39 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 42.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -34.0% | ||
| Liquidity | 37 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.22M NOK | ||
| Zero-volume days | 10.0% | ||
| Income | 43 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.7% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +9.1% |
|---|---|
| 1 month | +22.0% |
| 3 months | +32.2% |
| 6 months | +37.0% |
| 1 year | +33.5% |
| 3 years | +78.8% |
| 5 years | – |
Signals
| 50-day / 200-day average | 249.66 / 232.68 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 5.53 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 7 May 2026 | NOK 8.0000 |
| 9 May 2025 | NOK 6.0000 |
| 25 Apr 2024 | NOK 4.5000 |
| 25 Apr 2023 | NOK 4.5000 |
| 28 Apr 2022 | NOK 3.7500 |
| 28 Apr 2021 | NOK 3.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.